You are here
Phase 2 Clinical Trial of Vascular Endothelial Growth Factor-2 in Severe Cardiovascular Disease Commences
The trial, as previously announced, will be a national, randomized, double-blinded, dose ranging and placebo controlled study of up to 404 patients in up to 20 centers in the United States evaluating the efficacy and safety of defined doses of Vascular Endothelial Growth Factor-2 (VEGF-2) to be percutaneously delivered via Boston Scientific Corporation's (NYSE: BSX) Stiletto(TM) endocardial direct injection catheter. The trial will enroll qualified patients with Class III or IV angina. Patient enrollment is expected to commence during the third quarter.
Richard E. Otto, President and CEO, of Corautus stated, "Obtaining FDA approval to commence our Phase IIB clinical trial is an important milestone for Corautus. We have worked diligently with Boston Scientific to design a study to assess the effectiveness and safety of our therapeutic and the delivery system to promote angiogenesis in the heart and we are pleased that we can proceed to finalize documentation and begin the patient enrollment process."
Source: Corautus Genetics Inc.